Delivers real-time biopharma news and signals — powered by AI, curated for professionals.
OnMed, a healthcare technology company known for its innovative CareStation kiosks, has announced a significant expansion of its services into the education sector while simultaneously pursuing plans to go public. This move marks a pivotal moment in the company's growth strategy and highlights the increasing demand for accessible healthcare solutions.
Eli Lilly has secured a significant victory for its BTK inhibitor Jaypirca (pirtobrutinib), as the U.S. Food and Drug Administration (FDA) grants approval for its use in earlier treatment lines for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This development marks a crucial expansion of Jaypirca's potential impact in the treatment landscape for these slow-growing forms of non-Hodgkin lymphoma.
Avetra, a new contract research organization (CRO) based in North Carolina, has emerged on the pharmaceutical industry landscape with a mission to modernize clinical research operations. The self-proclaimed "next-gen" CRO aims to address longstanding industry frustrations by prioritizing transparency, faster study starts, and a site-centric operating model.
Medtronic has achieved a significant milestone in the rapidly evolving field of robotic surgery with the U.S. Food and Drug Administration (FDA) granting clearance for its Hugo robotic-assisted surgery (RAS) system. This development marks a pivotal moment in the medical device industry, potentially reshaping the landscape of minimally invasive surgical procedures in the United States.
Harmony Biosciences has reported positive results from a Phase III open-label extension study of its drug EPX-100 for the treatment of Dravet syndrome, a rare and severe form of epilepsy. The study demonstrated a significant reduction in seizure frequency and a favorable safety profile, potentially positioning EPX-100 as a promising new therapy for patients with this challenging condition.
The pharmaceutical industry faced a new challenge this week as a leaked memo from Dr. Vinay Prasad, Director of the FDA's Center for Biologics Evaluation and Research (CBER), claimed that COVID-19 vaccines have caused the deaths of at least 10 children. This revelation has sent shockwaves through the vaccine sector, causing stocks to slip and igniting a heated debate among experts calling for more substantial evidence to support these claims.
Pharvaris has announced a significant breakthrough in the treatment of hereditary angioedema (HAE), with its oral medication deucrictibant demonstrating impressive results in a phase 3 clinical trial. This development positions the biotech company to file for regulatory approval and potentially challenge KalVista Pharmaceuticals' Ekterly in the market for rapid HAE relief.
In a significant move for the gastrointestinal robotics sector, Swan EndoSurgical, a startup formed by Olympus and Revival Healthcare Capital, has named Erik Todd as its new CEO. Todd, a former Stryker executive with 25 years of experience, brings a wealth of expertise in medical robotics to the fledgling company.
Laboratoires Théa has entered into a significant agreement with Iolyx Therapeutics, potentially worth up to $280 million, to acquire the rights to ILYX-002, a phase 3-ready drug for moderate to severe dry eye disease (DED) associated with systemic autoimmune or inflammatory conditions.
Muvon Therapeutics has announced encouraging phase 2 trial results for its novel cell therapy approach to treating stress urinary incontinence (SUI), potentially offering an alternative to synthetic implants. The small-scale study demonstrated significant reductions in incontinence episodes and urine loss, marking a notable advancement in regenerative medicine for urological conditions.
Novo Nordisk and Eli Lilly's recent pricing agreements for their GLP-1 obesity treatments have set the stage for potential new entrants in the cardiometabolic space, according to a 2026 preview report from PitchBook. The deals, part of the TrumpRx initiative, are expected to expand the addressable market and streamline the regulatory pathway for future competitors.
In recent years, the pharmaceutical industry has witnessed a significant shift in venture capital funding for women-founded biopharma companies. Despite the challenges posed by the post-pandemic environment, these companies have continued to attract substantial investments, contributing to the sector's innovation and growth.
